Circulating blood lipid levels are heritable, treatable, risk factors for cardiovascular disease, a leading cause of death globally 1, 2 . Understanding the genetic basis of lipid levels in humans can identify targets for new, improved therapies for cholesterol management and prevention of heart disease 3 . Genome-wide association studies (GWAS) for plasma lipid levels have so far identified association with 157 loci 4, 5 , represented primarily by one or more common variants (minor allele frequency (MAF) >5%) with small effect sizes. These GWAS variants together explain ~12-14% of the trait variation in lipid levels, corresponding to 20-30% of the total genetic contribution to these traits 6 . Some of the missing heritability may be due to low-frequency (MAF = 1-5%) and rare (MAF < 1%) variants that are not well tested by GWAS [7] [8] [9] . These low-frequency and rare variants are plentiful in the genome 10,11 but are difficult to capture on GWAS chips, either directly or through imputation [12] [13] [14] .
Systematic assessment of association between blood lipid levels and coding variants has several potential benefits. First, it could implicate new loci in the regulation of blood lipids. Second, it could lead to the discovery of new lipid-modifying alleles at known loci that point to candidate causal genes. In some cases in which GWAS signals are shadows of a nearby rare variant with much larger effects, these alleles could be critical in directing follow-up functional experiments. For example, in PCSK9, a low-frequency functional variant explains the nearby common variant GWAS signal 15 , suggesting that the GWAS variant has no relevant functional consequence and would not be a productive target for functional experiments. Even when they do not account for the GWAS signal, rare coding variants in known loci can pinpoint specific genes as candidates for follow-up and functional analyses and clarify the biology. A good example of the latter situation is IFIH1, for which multiple independently associated loss-of-function Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk Blood lipid levels are heritable, treatable risk factors for cardiovascular disease. We systematically assessed genome-wide coding variation to identify new genes influencing lipid traits, fine map known lipid loci and evaluate whether low-frequency variants with large effects exist for these traits. Using an exome array, we genotyped 80,137 coding variants in 5,643 Norwegians. We followed up 18 variants in 4,666 Norwegians and identified ten loci with coding variants associated with a lipid trait (P < 5 × 10 −8 ). One variant in TM6SF2 (encoding p.Glu167Lys), residing in a known genome-wide association study locus for lipid traits, influences total cholesterol levels and is associated with myocardial infarction. Transient TM6SF2 overexpression or knockdown of Tm6sf2 in mice alters serum lipid profiles, consistent with the association observed in humans, identifying TM6SF2 as a functional gene within a locus previously known as NCAN-CILP2-PBX4 or 19p13. This study demonstrates that systematic assessment of coding variation can quickly point to a candidate causal gene.
A r t i c l e s variants, identified through GWAS, show that disabling this gene reduces the risk of type 1 diabetes 16 .
In this study, we systematically assess coding variants for association with lipid levels. Through chip-based genotyping of >80,000 coding variants (>68,000 with MAF < 5%) and follow up of interesting variants, we identify associated coding variants in ten loci. Nine of these variants point to genes with well-established roles in lipid metabolism, and the tenth (encoding p.Glu167Lys in TM6SF2) suggests a causal gene in a previously described GWAS locus 17, 18 . Follow-up experiments in mice show that overexpression of human TM6SF2 raises total cholesterol compared to a control construct and that knockdown of endogenous Tm6sf2 decreases total cholesterol, consistent with this gene being involved in regulating blood lipid levels.
RESULTS

Genotyping of discovery sample and assessment of coverage
To systematically assess the role of coding variants in lipid levels, we successfully genotyped 5,771 Norwegian participants from the population-based Nord-Trøndelag Health Study (the HUNT study) 19 for 234,187 variants using the Illumina HumanExome BeadChip arrays. Among the 5,643 (97.8%) analyzed individuals passing quality control, 80,137 coding variants were polymorphic in our sample, 68,615 of which had a frequency <5% ( Table 1) . We considered coding variants to refer to protein-altering variants: premature stop, essential splice donor or acceptor, readthrough or missense. The clinical characteristics of the stage 1 study participants are summarized in Supplementary Table 1 .
To quantify array coverage of all coding variation present in our Norwegian sample, we performed low-pass whole-genome sequencing with exome enrichment on 152 samples (2.7% of the stage 1 sample). The average sequencing depth was 45× for the exome target capture regions. We identified 46,170 coding variants in our sample through sequencing (5,648 on average per individual). The concordance between non-reference sequencing-based genotypes (>10× depth) and exome array genotypes was >99% for all allele frequencies (Online Methods). Among variants observed in more than one sequenced sample, we estimate that 70.9%, 77.4% and 78.0% of rare, low-frequency and common coding variants (MAF < 1%, MAF = 1-5% and MAF > 5%, respectively) were successfully genotyped using the array ( Table 1) . Most of the rare and low-frequency coding variants identified through sequencing and typed on the array have not been examined in previous lipid GWAS and cannot be imputed accurately using HapMap or 1000 Genomes reference panels 4, 5 , providing unique opportunities for evaluating the effect of lowfrequency variants on lipid levels.
Evaluation of known lipid signals
To validate our approach, we tested for association at known GWAS loci. Among the 157 previously described independent lipidassociated SNPs 4 , 127 were directly genotyped on the exome array. For the remaining 30 SNPs not genotyped, 17 were discovered after the array was designed, and 13 failed array design. Among the 127 variants examined, we identified genome-wide significant association at 7 (the probability that 7 or more loci exceed P < 5 × 10 −8 is P binominal = 5 × 10 −41 ) and nominal association (P < 0.05) at 45 (probability that 45 or more loci exceed P < 0.05 is P binominal = 3 × 10 −27 ). We compared the effect sizes for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, total cholesterol (TC) and triglycerides (TGs) observed in our nonfasting samples to those observed in much larger GWAS reports 4 and found a high degree of correlation (LDL r 2 = 0.46, HDL r 2 = 0.75, TC r 2 = 0.47, TGs r 2 = 0.84; Supplementary Fig. 1) .
Furthermore, when we examined lipid traits individually, the direction of effect for the associated SNPs matched that reported in GWAS 4 for 79%, 83%, 85% and 90% of variants (HDL, TGs, LDL and TC, respectively; Supplementary Table 2), suggesting high reliability of the array genotype data for our downstream analyses.
Follow-up genotyping and summary of association results
We next tested for association between coding variants with at least six copies of the minor allele (51,453 coding variants) and lipid measurements in our stage 1 samples (n = 5,643). We saw no evidence for inflation of test statistics (LDL λ GC = 1.04, HDL λ GC = 1.06, TC λ GC = 1.08, TG λ GC = 1.04; Supplementary Fig. 2 ). We selected for replication coding variants with P < 2 × 10 −5 , MAF < 10% and minor allele count >5 to capture variants that are less likely to be covered by GWAS but with enough rare alleles to allow for association testing. We examined 18 top variants in 4,666 Norwegian individuals from the population-based Tromsø study 20 (stage 2). The clinical characteristics of the stage 2 study participants are summarized in Supplementary Table 1. We performed a joint association analysis in stage 1 and stage 2 samples (n = 10,309). We considered the threshold for significance as 5 × 10 −8 to be consistent with GWAS.
This design had 80% power to detect variants with MAF = 1% and effect size of 0.44 s.d. units (Fig. 1) at α = 5 × 10 −8 . As expected, power varies with allele frequency, so we have 80% power to detect common variants with MAF = 10% and effect size of 0.15 s.d. and equivalent power for variants with MAF = 0.5% and effect size of 0.62 s.d. 
A r t i c l e s
Overall we identified coding variants in 11 genes that reach genome-wide significance ( Table 2) . Most of these variants map to genes whose roles in lipid metabolism are now well established (APOE, APOB, ABCG5, ABCG8, CETP, LIPC, LIPG, APOA5 and LPL), but two map to genes (RNF111 and TM6SF2) that have not been implicated previously in blood lipid levels. We will first briefly summarize our results at the known loci before dissecting our results at RNF111 and TM6SF2 in greater detail. Further details of the association results are given in Supplementary Table 3 and Supplementary Figure 2 .
Variants in previously implicated genes
To explore the relationship between coding variants identified in our experiment and previously identified GWAS signals, we performed conditional analysis evaluating the association at each coding variant after accounting for each nearby GWAS index SNP and vice versa. In addition, to define a list of independent association signals at each locus, we performed a conditional analysis adjusting for all previously known lipid-associated SNPs.
LDL cholesterol and variants in APOE, APOB, ABCG5 and ABCG8
We identified LDL-associated coding variants in four previously implicated genes: APOE, APOB and at ABCG5 and ABCG8 (which are adjacent genes that share a promoter on chromosome 2). Variants at three of these genes (APOB, ABCG5 and ABCG8) were also associated with TC levels, which is consistent with the strong correlation between LDL and TC levels. Dissection of the association signals at the three loci suggested different relationships between coding variants and previously reported GWAS signals.
The coding variant at APOB (rs1367117, encoding p.Thr98Ile) was previously identified as the GWAS index SNP for LDL and TC 4, 5 . In contrast, at APOE, association signals with rs7412 (encoding p.Arg176Cys; Table 2 ) and the GWAS index SNP (rs4420638) appeared to be mostly independent (Supplementary Table 4 ). The p.Arg176Cys variant is one of two SNPs that determine well-known functional haplotypes in APOE 21 , and the GWAS index SNP is thought to be a shadow of rs429358 (encoding p.Cys130Arg), the other functional SNP in the gene, which is difficult to genotype and was not successfully assayed in our samples.
At ABCG5 and ABCG8, coding variants (resulting in ABCG5 p.Arg50Cys and ABCG8 p.Asp19His, both MAF = 6.5%) were assayed in GWAS 4 , but an intronic SNP (rs4299376) was assigned as the GWAS index SNP because of stronger evidence for association. Conditional analysis in our samples shows that the signal at the two highly correlated ABCG5-ABCG8 missense variants is only modestly attenuated and is thus likely to be independent from the GWAS index SNP (the P value in stage 1 decreased from P = 1 × 10 −7 to P conditional = 3 × 10 −6 ; Supplementary Table 4) .
Triglycerides and variants in APOA5, LPL and ANGPTL4
We identified TG level-associated coding variants in three genes, APOA5, LPL and ANGPTL4. Although ANGPTL4 is a locus that has also been identified through GWAS, the low-frequency variant encoding p.Glu40Lys (rs116843064, MAF = 3.2%, P stage 1 = 8 × 10 −9 ) shows significant association even in the absence of a significant signal at the nearby GWAS index SNP (rs7255436, P stage 1 = 0.066; Supplementary Table 4 ), suggesting that the two are independent or that the GWAS index SNP is a weak proxy for p.Glu40Lys. Associations at the variants encoding p.Ser19Trp in APOA5 (rs3135506, MAF = 6.1%) and p.Ser474* in LPL (rs328, MAF = 9.6%, previously known as p.Ser447*) were completely attenuated by conditioning on the nearby GWAS index SNPs (rs964184 and rs12678919, respectively; Supplementary Table 5 ). In APOA5, the GWAS SNP still showed association after adjusting for the coding variant (P conditional = 2 × 10 −21 ), suggesting that p.Ser19Trp is a shadow to the GWAS variant. In LPL, the GWAS signal was completely attenuated (P = 0.96) by the coding variant, suggesting that the effects of these variants on TG levels are statistically indistinguishable.
HDL cholesterol and variants in CETP, LIPC and LIPG
We identified four HDL-associated coding variants in three previously implicated genes: CETP (two variants), LIPC and LIPG ( Table 2) . In all three genes, these variants show significant association even after adjusting for nearby GWAS index SNPs (Supplementary Table 4 ). Three of the HDL-associated variants were low frequency (MAF < 5%) and are thus beyond the reach of traditional GWAS genotyping arrays and imputation. The ancestral alleles at two variants in CETP (alanine at position 390 and valine at position 422) were associated with increased HDL cholesterol (Supplementary Table 4 ). The p.Thr405Met variant (rs113298164, P = 6 × 10 −6 , MAF = 0.7%, previously known as p.Thr383Met) in LIPC, the hepatic lipase gene, was the only rare coding variant (MAF < 1%) that we identified to be associated with a lipid trait. The p.Thr405Met variant has been observed previously in families with hepatic lipase deficiency, a disease that results in elevated lipid levels and TG-rich HDL subfractions 22 but until now had not been associated with HDL cholesterol in population samples ( Supplementary  Fig. 3a) . Conditional analysis demonstrates that this association signal appears to be independent of the two common variants that show association 5′ of the gene 5 (P conditional = 8 × 10 −9 , adjusting for rs1532085 and rs261334; Supplementary Fig. 3c ). Figure 1 Power estimates for the current study compared to the estimated effect sizes for coding variants and GWAS index SNPs. The 'variant' column lists predicted changes in amino acid sequence using ANNOVAR 34 . MI association results were determined from 2,350 medical record-confirmed cases with MI and 2,318 healthy controls in our stage 1 samples.
At the APOA5 locus, the p.Ser19Trp variant showed weaker evidence for association with TG levels than the GWAS index SNP, indicating that the coding variant may not be functional. Rare variant association with RNF111 due to LIPC variant We were intrigued initially by association between the rare variant encoding p.Pro836Ser in RNF111 (rs181181625, MAF = 0.46%) and HDL cholesterol (P = 3 × 10 −9 ). The gene is >500 kb from any known GWAS index SNPs (Table 2) , and the association remained significant after adjusting for the top GWAS association signals in the chromosome, both coding and noncoding. Interestingly, the variant appears at low frequencies in Norwegians (MAF = 0.46% in n = 10,309) and Estonians 23 (MAF = 0.30% in n = 9,328) and is absent in the other samples we examined: 2,979 Dutch individuals from the Rotterdam Study 24 and 5,338 Hispanic Americans and 4,216 African Americans from the Mount Sinai BioMe study 25 .
A detailed conditional association analysis to identify independently associated variants on chromosome 15 revealed that the RNF111 p.Pro836Ser variant shows no evidence for association after accounting for the variant encoding LIPC p.Thr405Met located 522,192 bases away (P conditional = 0.82; Supplementary Table 4 and Supplementary Fig. 3 ). Longrange linkage disequilibrium (LD; r 2 = 0.60) between the two variants suggests that the RNF111 variant might have arisen on the LIPC p.Thr405Met haplotype in a common ancestor of Norwegians and Estonians.
Having dissected associated variants in familiar loci and recognized the potentially novel signal in RNF111 as a shadow of rare variant signals in LIPC, we turned our attention to coding variants in an unfamiliar gene that showed significant association with TC.
Identification of TM6SF2 as a causal gene for TC In TM6SF2, the p.Glu167Lys variant (rs58542926, MAF = 8.9%) reached the threshold for genome-wide significant association with TC (P = 4 × 10 −8 ; Supplementary  Fig. 4) Supplementary Fig. 4 ). This locus also harbors a coding variant in NCAN (rs2228603, encoding p.Pro92Ser) that is in moderately strong LD with the index SNP (r 2 = 0.71), but the variant encoding TM6SF2 p.Glu167Lys shows stronger evidence for association in our sample (Supplementary Table 3d ) and a higher r 2 value with the GWAS index SNP (r 2 = 0.97). Both p.Glu167Lys in TM6SF2 and p.Pro92Ser in NCAN are classified as 'probably damaging' by PolyPhen2 (PolyPhen scores of 0.996 npg A r t i c l e s and 0.957, respectively) 26 . However, NCAN is expressed primarily in the brain 27 and is not a strong candidate for having a role in lipid biology. There are 21 genes within the GWAS association signal, and before this study, it was unknown which of these genes mediate the observed association signal. In our sample, the TC associations for the p.Glu167Lys TM6SF2 coding variant and the GWAS index SNP are indistinguishable, suggesting that the coding variant could be causal. Specifically, after conditioning on the coding variant, the TC association at the GWAS index SNP becomes nonsignificant (P conditional = 0.65; Supplementary Table 4), demonstrating that the TM6SF2 variant accounts for the association signal detected by GWAS. In silico look up in 92,605 European samples genotyped with the Metabochip 4 confirmed strong evidence for association with TC (P = 1 × 10 −47 ; Supplementary Table 5), LDL cholesterol (P = 2 × 10 −38 ) and TG levels (P = 9 × 10 −50 ).
To further test whether TM6SF2 might be the functional gene at this locus, we determined the tissue distribution pattern of TM6SF2 in C57BL/6J mice by northern blotting and western blotting. Endogenous Tm6sf2 was highly expressed in the liver at both the mRNA and protein levels, suggesting a potential role of TM6SF2 in hepatic lipid metabolism (Supplementary Fig. 5 ). Next, we transiently overexpressed human TM6SF2 in C57BL/6J mice using a livertargeting adenovirus containing the human TM6SF2 coding region (Ad-TM6SF2) and compared lipid levels in these mice to those in mice injected with a control adenovirus construct containing lacZ (Ad-lacZ). Five days after tail-vein injection, the protein levels of TM6SF2 in Ad-TM6SF2-transduced mouse livers were 2.4-fold increased when compared with Ad-LacZ-transduced livers (Fig. 2c) . In TM6SF2-overexpressing mice compared to mice injected with the control construct (lacZ), TC, LDL cholesterol and TG levels were increased (TC: 2.3-fold, P = 9 × 10 −4 ; LDL: 5.8-fold, P = 4 × 10 −4 , TGs: 1.13-fold, P = 0.031), and HDL cholesterol levels were decreased (0.45-fold, P = 9 × 10 −4 ; Fig. 2) .
We additionally tested the impact of knockdown of Tm6sf2 by transient transduction of short hairpin RNA (shRNA) against Tm6sf2 in C57BL/6J mice using an adenovirus. Six days after tail-vein injection, the protein levels of TM6SF2 were decreased by 49% in the liver of Tm6sf2 knockdown mice (Fig. 2) . We found that fasting TC levels were decreased by 18.2% in Tm6sf2 knockdown mice compared to controls (P = 0.013, n = 16 mice; Fig. 2) . Given that overexpression of TM6SF2 increases TC and knockdown of Tm6sf2 decreases TC and that the minor human allele is associated with reduced cholesterol, our results suggest that the presence of a positively charged amino acid (lysine) at codon 167 results in decreased function of TM6SF2 relative to the negatively charged amino acid (glutamic acid) that is observed more commonly.
Association with myocardial infarction and liver disease
Our stage 1 sample included 2,833 medical record-confirmed cases with myocardial infarction (MI) and 2,938 healthy controls matched on sex and birth year. In addition, our stage 2 follow-up sample included 2,349 medical record-confirmed cases with MI and 2,317 controls. This allowed us to test for association with MI in the same individuals in which the lipid associations were identified.
We observed suggestive association with MI for coding variants in two genes associated with lipid traits: TGs (ANGPTL4, rs116843064, odds ratio (OR) = 0.78, P = 0.003) and TC (TM6SF2, rs58542926, OR = 0.87, P = 0.005). As expected, alleles associated with reduced lipid levels also conferred a reduced risk of MI ( Table 2) .
At the TM6SF2 locus, the GWAS index SNP was associated with coronary artery disease in a large sample of 20,597 cases and 61,046 controls 28 (rs10401969, OR = 0.90, 95% confidence interval (CI) 0.85-0.95, P = 2 × 10 −4 ). As previous reports have described an association with the correlated NCAN p.Pro92Ser variant (rs2228603) at this locus and non-alcoholic fatty liver disease (OR = 1.65, P = 5 × 10 −5 ) 29 , we tested for association with serum alanine aminotransferase levels, a marker of liver damage. In human samples, we found modest evidence for association between serum alanine aminotransferase levels and the TM6SF2 p.Glu167Lys variant (rs58542926, n = 1,481, P = 7 × 10 −3 ) but not with NCAN p.Pro92Ser (rs2228603, P = 0.15). 
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A r t i c l e s
This finding is consistent with the possibility that TM6SF2 p.Glu167Lys may also be responsible for association of this locus with non-alcoholic fatty liver disease 29 .
We found no evidence of TG accumulation in the livers of any experimental or control mice, suggesting that neither TM6SF2 expression changes nor adenovirus injection caused any liver damage in our experimental model (Supplementary Fig. 6 ). We also found no significant differences in serum alanine aminotransferase levels in experimental compared to control mice after either overexpression of TM6SF2 or knockdown of Tm6sf2 (Supplementary Fig. 7) . We hypothesize that the absence of any liver disease phenotype in mice is due to transient exposure to altered TM6SF2 levels in contrast to a lifetime of exposure to altered TM6SF2 in humans carrying the Glu167-encoding allele in TM6SF2.
Gene-level association tests
To test rare and low-frequency variants for association, we performed gene-based burden tests for LDL cholesterol, HDL cholesterol, TC and TGs. Using both CMC 30 and SKAT-O 31 statistical tests, we selected missense and loss-of-function variants using three allele frequency thresholds: MAF < 5%, MAF < 1% and MAF < 0.1%. There were no genes that reached exome-wide significance (P < 5 × 10 −7 ) that were not already highlighted by single variant association tests (Supplementary Table 6 ). However, for three genes, the strength of association with a burden of rare variants was more significant than that observed for a single variant test, and in each case, we observed a second nominally significant variant encoding: LIPG p.Arg476Trp for HDL cholesterol (MAF = 0.18%, P = 9 × 10 −4 ), LIPC p.Arg208His for LDL cholesterol (MAF = 0.16%, P = 0.02) and ANGPTL4 p.Arg336Cys for TGs (MAF = 0.24%, P = 0.01). When we examined 104 additional missense or loss-of-function variants in the ten genes using a reduced threshold for significance (P < 5 × 10 −4 ), only one low-frequency variant was associated with any lipid trait: LPL p.Asn318Ser (P = 1 × 10 −4 , MAF = 3.2%) with TGs (Supplementary Table 7) .
DISCUSSION
By examining a substantial fraction of the coding variants in >10,000 Norwegians, we identified significant association at ten loci, highlighting one novel functional gene (TM6SF2) at a GWAS locus for TC and nine known functional genes: APOE, APOB and ABCG5-ABCG8 for LDL cholesterol; APOA5, LPL and ANGPTL4 for TG levels; and CETP, LIPC and LIPG for HDL cholesterol.
Of the ten genome-wide significant variants, we identified two rare or low-frequency coding variants that had not been identified previously in population-based association studies: variants encoding LIPC p.Thr405Met for HDL cholesterol and ANGPTL4 p.Glu40Lys for TGs. This finding suggests that there are likely additional lowfrequency variants that were not detected by GWAS, a subset of which may have been previously identified by candidate gene studies or in families with dyslipidemia. Although this study had 80% power to detect variants with MAF = 1% and effect size of 0.44 s.d. and was able to exclude the possibility that large numbers of such variants exist, we have only modest power to detect rare variants with smaller effects. Subsequent studies in larger sample sizes will be required to determine the proportion of heritability that can be explained by rare or low-frequency variants.
The effect (0.7 s.d., 10.5 mg dl −1 ) of the rare missense p.Thr405Met variant in LIPC identified for HDL cholesterol was larger than that for any lipid variant previously observed from GWAS (maximum effect size of 0.3 s.d.). This variant, with an allele frequency of 0.7% in Norwegians, highlights the importance of evaluating low-frequency variants for large effect sizes on lipid levels. This variant was most likely not captured by GWAS because (i) it is not present in HapMap; (ii) variants with <1% frequency are not typically analyzed for association in GWAS; and (iii) low-frequency variants are difficult to impute accurately. Despite its large effect size, this variant also illustrates challenges in rare variant studies: the observed association was more significant for common variants with smaller effect sizes, and individually these common variants accounted for more of the trait heritability. Identifying association with rare variants at the population level may require very large sample sizes even when their effect sizes are large.
The coding variants identified in our study (three to four variants per trait) explained between 1.9% (for TG levels) and 4.5% (for LDL cholesterol) of the trait variance (3.4% for HDL cholesterol and 3.1% for TC). In future clinical settings in which genomic sequence might be available in patients, the evaluation of genetic risk scores would be improved by incorporating these variants, as well as others yet to be discovered, with a relatively high impact on lipid levels. However, the effect size (although substantially higher per coding variant than for noncoding variants identified by GWAS) may have no relation to the potential importance of the gene as a drug target. For example, noncoding variants near HMGCR have a small impact on LDL cholesterol levels (~2.4 mg dl −1 ) 5 , but disruption of this gene's protein by statins can have a substantial impact on an individual's LDL cholesterol levels (average decrease of 40 mg dl −1 ) 32 .
More importantly, the study of coding variants may quickly point to the functional gene, as we have demonstrated for TM6SF2. For loci at which LD extends over a large region containing many genes, as is the case for TM6SF2, functional experiments on a large number of genes would be extremely challenging 33 . Instead, identification of an associated coding variant allowed us to prioritize one gene previously unknown to be involved in regulation of blood lipid levels as a functional gene.
Functional follow up by overexpressing the human form of TM6SF2 in mice confirmed the gene as an attractive functional candidate in the locus previously known as NCAN 4, 17 , CILP2 (ref. 5), PBX4 (ref. 18) or 19p13 (ref. 18) . In mice, overexpression of human TM6SF2 resulted in higher TC, LDL cholesterol, TGs and lower HDL cholesterol, whereas knockdown of Tm6sf2 resulted in decreased TC. Consistent with the expectation that increased cholesterol levels cause cardiovascular disease, in humans we found that the Glu167-endoding allele that was associated with reduced TC also confers a reduced risk of MI (OR = 0.87, 95% CI 0.79-0.93, P = 0.005; Table 2 ). Additional experiments will be needed to clarify the value of TM6SF2 as a potential drug target.
We expect that additional coding variants with association to lipid traits will be identified using larger sample sizes, as well as expanded coverage of coding variation not assayed in this study. However, our results, in particular the identification of a common coding variant and functional gene, TM6SF2, illustrate the value of systematic studies of coding variation in identifying lipid-associated genetic variation that is relevant for the prevention of cardiovascular disease.
ONLINE METHODS
Subjects. We selected samples from two large population-based cohorts in Norway. Clinical characteristics of the study participants are provided in Supplementary Table 1 .
The HUNT study (stage 1). We included 5,771 individuals with at least one lipid measurement from the second survey of the Nord-Trøndelag Health Study (HUNT): 2,833 cases with hospital-diagnosed MI (primary phenotype) and 2,938 healthy controls without cardiovascular disease matched on sex, birth year (±1 year) and municipality or geographical region to minimize population stratification. HUNT is a population-based health study with personal and family medical histories on approximately 120,000 individuals from Nord-Trøndelag County, Norway collected in three surveys (HUNT 1, 2 and 3) 19, 35 . HUNT 2 was conducted in 1995-1997, inviting all residents ≥20 years of age in Nord-Trøndelag County, Norway. Self-reported questionnaires, clinical examination and non-fasting venous blood samples were collected on 62,816 individuals (66.9% of those invited). The population of Nord-Trøndelag County is ethnically homogenous (<3% non-Caucasian ethnicity), making it especially suitable for epidemiological genetic research 35 .
The Tromsø Study (stage 2). We included for follow up 4,666 individuals from the fourth wave of the Tromsø Study (Tromsø 4): 2,349 cases with hospital-diagnosed MI (primary phenotype) identified retrospectively and 2,317 controls without cardiovascular disease matched on sex and birth year (±2.5 years). The Tromsø Study is a population-based health study with medical histories on approximately 40,000 individuals of the Tromsø municipality, North Norway collected with six surveys (Tromsø 1-6). Tromsø 4 was conducted in 1994-1995 with questionnaires, clinical examination and nonfasting venous blood samples from 27,158 individuals ≥25 years of age 20 .
Laboratory measurements. Clinical chemical analyses were conducted on fresh venous non-fasting blood samples (16% of HUNT participants and 25% of Tromsø Study participants reported ≥4 h of fasting before the blood draw) at Levanger Hospital (stage 1) or the University Hospital of North Norway (stage 2). TC, HDL cholesterol and TGs were measured by an enzymatic colorimetric method using a Hitatchi 911 Auto-Analyzer (stage 1) and applying commercial kits from Boehringer Mannheim (both stages). HDL cholesterol was measured after precipitation with phosphotungstate and magnesium ions (stage 1) or heparin and manganese chloride (stage 2). Day-to-day coefficients of variation were 1.3-1.9% for TC, 2.4% for HDL cholesterol and 0.7-1.3% for TGs (stage 1). Alanine aminotransferase was measured by NADH (with P-5′-R) methodology using Architect cSystems ci8200 (Abbot Diagnostics) and activated alanine aminotransferase assays (Abbot Laboratories, Reagent kit 8D36-30, 3913/R3). Day-to-day coefficients of variation were 3.4% in the low range and 1.8% in the high range.
Phenotypes. Serum measurements. Associations are reported for four lipid traits: LDL cholesterol, HDL cholesterol, TC and TGs. LDL cholesterol was calculated using the Friedewald formula 36 . Information on lipid-lowering medication was not available for the cohorts studied. The use of statins for primary prevention purposes was rare in Norway in the 1990s and early 2000s. For liver enzyme, the association is reported for alanine aminotransferase.
MI. We identified acute MI retrospectively by linking our study participants to the electronic diagnosis registry of the two local hospitals in NordTrøndelag County (stage 1) and the University Hospital of North Norway (stage 2) using the 11-digit national identifying number unique to every citizen of Norway. For stage 1, we identified MI events registered as the principal diagnosis (ICD-10 I21 or ICD-9 410) in a medical department from December 1987 to June 2011. For stage 2, MI events were registered from the time of enrollment in the Tromsø Study to December 2010, and an adjudication of hospitalized and out-of-hospital events was performed by an independent endpoint committee using data from hospital and out-of-hospital journals, autopsy records and death certificates (when applicable). Stage 1 controls were selected among HUNT 2 study participants with DNA available (n = 62,816) after excluding those with self-reported and/or hospital-diagnosed MI, MI in first-or second-degree family members, cardiovascular disease, diabetes or hypertension. Stage 2 controls were selected among the Tromsø 4 study participants with DNA available (n = 27,158) after excluding those with cardiovascular disease.
Stage 1 genotyping. We attempted genotyping of 5,771 HUNT individuals at the Genomic Core Facility, Norwegian University of Science and Technology, Norway using the HumanExome-12v1_A BeadChip (Illumina) and the Infinium HD ultra protocol. The exome array includes 247,870 markers focused on protein-altering variants (nonsynonymous, splicing and stopaltering) selected from >12,000 exome and genome sequences, including variants that have been associated with complex traits in previous GWAS, HLA tags, ancestry-informative markers, markers for identity-by-descent estimation and random synonymous SNPs. Details about SNP content and selection strategies can be found at the exome array design webpage.
Quality control of genotypes. Each 96-well plate included both cases and control individuals at random order and one internal blind sample present on each plate. Genotype calling was done on GenTrain version 2.0 in GenomeStudio V2011.1 (Illumina) in combination with zCall version 2.2 (ref. 37) . Samples below 99% genotype completion rate and samples expressing gender discrepancy or a high level of heterozygosity (−0.05 < F (inbreeding coefficient) < 0.1) were excluded from further analysis (n = 128, 2.22%). In addition, SNPs that did not meet the 99% genotyping threshold or showed deviation from Hardy-Weinberg equilibrium (P < 1 × 10 −5 ) were removed (13,683 SNPs). After quality assessment, 234,187 SNPs (94.5%) on 5,643 (97.8%) individuals remained for further analysis, 99,854 (42.6%) of which were not monomorphic. Of these SNPs, 80,137 were coding variants, and 68,615 of these coding variants had a frequency <5% ( Table 1) .
Whole-genome sequencing. We performed low-pass whole-genome sequencing with exome enrichment (SeqCap EZ Human Exome Library v3.0, Roche NimbleGen Inc.) on 76 cases with MI and 76 controls at the University of Michigan DNA Sequencing Core using the Illumina HiSeq 2500. The average sequence coverage was 45× for the capture regions. Concordance for non-reference genotypes between genome sequenced samples (>10× depth) and exome array genotypes was 99.4% for variants with >5% frequency, 99.7% for variants with 1-5% frequency and 99.5% for variants with frequency <1%.
Stage 2 genotyping.
On the basis of preliminary results from stage 1, we selected for replication single variants with P < 2 × 10 −5 , MAF < 10% and minor allele count >5 to capture variants that are less likely to be covered by GWAS but with enough variants to have a reasonable possibility of replication. We attempted SNP-based follow up in 4,666 individuals at the Centre for Integrative Genetics, Ås, Norway using iPLEX Gold MassARRAY technology (Sequenom). Of the 22 SNPs meeting our initial replication threshold, 4 failed array design and were excluded before genotyping.
Statistical analyses.
Assuming an additive genetic model, we tested for trait-SNP association with lipid levels using linear regression with covariates for age, sex, primary phenotype (MI status: yes or no) and principal components 1 and 2 as implemented in PLINK 38 . We evaluated the impact of cryptic relatedness using a linear mixed model (EMMAX) 39 and found the results to be highly correlated with linear regression (Pearson r 2 = 0.85, P < 2.2 × 10 −16 ). Lipid values were transformed to rank-based inverse-normal residuals to reduce the impact of outliers. Each individual's rank was calculated on the basis of the total number of individuals with available lipid measurements and DNA in the two cohorts (5,643 individuals for stage 1 and 4,666 individuals for stage 2). We also performed conditional logistic regression, including the subset of lipid GWAS SNP(s) reported by Willer et al. 4 within 500 kb of our lead SNP as covariate(s), to identify additional association signals accounting for the effects at known and newly discovered lipid loci. We estimated the LD metric r 2 using 5,643 individuals from stage 1 who passed genotyping quality control. LD with SNPs not included on the exome array was estimated from 1000 Genomes EUR individuals. For lipids, we declared a single variant association to be significant if P < 5 × 10 −8 to be consistent with GWAS studies. For MI, we declared a single variant association to be significant if P < 0.005, corresponding to Bonferroni correction for the ten variants tested in Table 2 . Differences in mouse lipid levels were assessed using Mann-Whitney U test, in which P < 0.05 was declared significant. Statistical power of the association tests was estimated using the two-sample t tests model implemented in the R package pwr. 
